Marshall Wace North America’s Allogene Therapeutics ALLO Stock Holding History

Marshall Wace North America’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-325,040	Closed	-$8.48M	–	1406
2021 Q2	$8.48M	Buy	+325,040	New	+$9.27M	0.04%	408
2020 Q4	–	Sell	-13,878	Closed	-$523K	–	1285
2020 Q3	$523K	Buy	+13,878	New	+$523K	﹤0.01%	956
2020 Q2	–	Sell	-149,235	Closed	-$2.9M	–	1135
2020 Q1	$2.9M	Sell	149,235 -43,823	-23%	-$1.04M	0.02%	417
2019 Q4	$5.02M	Buy	+193,058	New	+$5.32M	0.02%	389
2019 Q3	–	Sell	-9,531	Closed	-$256K	–	1294
2019 Q2	$256K	Sell	9,531 -230,529	-96%	-$6.42M	﹤0.01%	1000
2019 Q1	$6.94M	Buy	+240,060	New	+$6.97M	0.05%	261

Other funds holding ALLO

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Marshall Wace North America's ALLO Position: Q3 2021 in Review

Marshall Wace North America sold out of Allogene Therapeutics (ALLO) in Q3 2021, closing a stake of 325,040 shares — an estimated $8.48M sold.

Marshall Wace North America first reported a position in ALLO in Q1 2019 and held it in 6 quarters. The position peaked at $8.48M in Q2 2021. 169 funds tracked by Wall St. Rank hold ALLO as of Q3 2021.

Marshall Wace North America reported no remaining Allogene Therapeutics position as of Q3 2021 after selling out during the quarter.
Marshall Wace North America sold 325,040 Allogene Therapeutics shares in Q3 2021, an estimated $8.48M.
Marshall Wace North America first reported a position in Allogene Therapeutics in Q1 2019 and held it in 6 quarters.
Marshall Wace North America's Allogene Therapeutics position peaked at $8.48M in Q2 2021.
169 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.